CONSOLIDATED STATEMENTS OF (LOSS) INCOME - USD ($) shares in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Revenues
Product sales	$ 2,443,600,000	$ 2,748,200,000	$ 7,168,400,000	$ 7,569,300,000
Other revenues	36,000,000	38,600,000	103,000,000	120,000,000
Total revenues	2,479,600,000	2,786,800,000	7,271,400,000	7,689,300,000
Operating Expenses
Cost of goods sold (exclusive of amortization and impairments of finite-lived intangible assets shown separately below)	649,200,000	634,600,000	1,916,700,000	1,812,400,000
Cost of other revenues	8,800,000	13,600,000	29,000,000	43,100,000
Selling, general and administrative	660,900,000	697,600,000	2,145,000,000	1,956,900,000
Research and development	100,800,000	101,600,000	328,200,000	238,500,000
Amortization and impairments of finite-lived intangible assets	807,100,000	679,200,000	2,389,200,000	1,629,800,000
Goodwill impairment	1,049,000,000	0	1,049,000,000	0	$ 0
Restructuring and integration costs	20,700,000	75,600,000	78,200,000	274,000,000
In-process research and development impairments and other charges	36,000,000	95,800,000	53,900,000	108,100,000
Acquisition-related costs	0	7,000,000	1,800,000	30,400,000
Acquisition-related contingent consideration	9,000,000	3,800,000	18,300,000	22,600,000
Other expense (income)	1,100,000	30,200,000	(21,600,000)	213,200,000
Total expenses	3,342,600,000	2,339,000,000	7,987,700,000	6,329,000,000
Operating (loss) income	(863,000,000)	447,800,000	(716,300,000)	1,360,300,000
Interest income	2,500,000	700,000	5,500,000	2,500,000
Interest expense	(469,600,000)	(420,200,000)	(1,368,700,000)	(1,130,700,000)
Loss on extinguishment of debt	0	0	0	(20,000,000)
Foreign exchange (loss) gain and other	(2,300,000)	(34,000,000)	4,600,000	(99,500,000)
(Loss) income before (recovery of) provision for income taxes	(1,332,400,000)	(5,700,000)	(2,074,900,000)	112,600,000
(Recovery of) provision for income taxes	(113,300,000)	(57,400,000)	(178,900,000)	14,000,000
Net (loss) income	(1,219,100,000)	51,700,000	(1,896,000,000)	98,600,000
Less: Net (loss) income attributable to noncontrolling interest	(700,000)	2,200,000	(1,600,000)	4,400,000
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.	$ (1,218,400,000)	$ 49,500,000	$ (1,894,400,000)	$ 94,200,000
(Loss) earnings per share attributable to Valeant Pharmaceuticals International, Inc.:
Basic (in usd per share)	$ (3.49)	$ 0.14	$ (5.47)	$ 0.28
Diluted (in usd per share)	$ (3.49)	$ 0.14	$ (5.47)	$ 0.27
Weighted-average common shares outstanding (in millions)
Basic (in shares)	349.5	344.9	346.5	340.8
Diluted (in shares)	349.5	351.0	346.5	347.2